Ads
related to: prolymphocytic leukemia treatment- Treatment Option
Visit The Physician Website To
Learn More About This Treatment.
- Clinical Trial Data
Physicians, Find Results And
Study Design Information.
- Dosing & Administration
Learn About Important Dosing
Considerations For This Rx.
- View Patient Profiles
Patients Experience Treatment
Intolerance & Suboptimal Responses
- Treatment Option
Search results
Results From The WOW.Com Content Network
B-cell prolymphocytic leukemia, referred to as B-PLL, is a rare blood cancer.It is a more aggressive, but still treatable, form of leukemia.. Specifically, B-PLL is a prolymphocytic leukemia (PLL) that affects prolymphocytes – immature forms of B-lymphocytes and T-lymphocytes – in the peripheral blood, bone marrow, and spleen.
T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and predilection for blood, bone marrow, lymph nodes, liver, spleen, and skin involvement. [1] T-PLL is a very rare leukemia, primarily affecting adults over the age of 30.
Most people with T-cell prolymphocytic leukemia, a rare and aggressive leukemia with a median survival of less than one year, require immediate treatment. [75] T-cell prolymphocytic leukemia is difficult to treat, and it does not respond to most available chemotherapeutic drugs. [75]
Alemtuzumab (Campath-1H) is an anti-CD52 humanized IgG1 monoclonal antibody indicated for the treatment of fludarabine-refractory chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma, peripheral T-cell lymphoma and T-cell prolymphocytic leukemia.
Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell prolymphocytic leukemia and T-cell prolymphocytic leukemia. It is usually classified as a kind of chronic lymphocytic leukemia .
The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant. The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). [7]
Ads
related to: prolymphocytic leukemia treatment